who is developing retatrutide 🚨 JUST RELEASED TODAY!!!! NEW PHASE 3 DATA Today, July 23, 2026, new Phase 3 retatrutide results were released, adding to what already one of the most interesting obesity drug Retatrutide UK | The Ultimate

Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs

Using sterile water eliminates the bacterial inhibitor, making the solution unsafe for repeated draws

The earliest UK private access via online pharmacies is likely in 2027 or 2028, with NHS access following a NICE appraisal

If lumps develop: These are usually localized swelling, not dangerous